Side-by-side · Research reference
GLP-1 (7-37)vsHGH Fragment 176-191
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED16/43 cited
BAnimal-StrongHUMAN-REVIEWED28/59 cited
GLP-1 (7-37)
Incretin Hormone · Native Peptide
Research use only · IV/SC in experimental settings
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
01Mechanism of Action
Parameter
GLP-1 (7-37)
HGH Fragment 176-191
Primary target
GLP-1 receptor (class B GPCR)Koole 2015
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
Pathway
GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025Koole 2015
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Downstream effect
Glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, reduced food intakeLu 2025Ding 2017
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Feedback intact?
Yes — physiological secretion and degradation preserved
N/A — does not interact with GH/IGF-1 axis
Origin
Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Antibody development
—
Not reported in available studies
02Dosage Protocols
Parameter
GLP-1 (7-37)
HGH Fragment 176-191
Clinical use
None — native GLP-1 not used therapeutically
Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024
—
Research dosing
Variable — 0.1–10 nmol/kg in animal models
Used as reference standard for analogue comparison.
—
Modified analogues
t½ extended to 13 h (liraglutide), 165 h (semaglutide)
Via DPP-4 resistance + fatty acid acylation.
—
Animal dose (IP)
—
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
Human equivalent dose
—
Not established — no published human RCTs
Frequency
—
Once daily (animal models)
Evidence basis
—
Animal studies only
Detection window
—
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
Oral bioavailability
—
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
03Metabolic / Fat Loss Evidence
Parameter
GLP-1 (7-37)
HGH Fragment 176-191
Mechanism
GLP-1R activation in hypothalamic satiety centers (arcuate nucleus) reduces food intakeLu 2025
Effect demonstrated with long-acting analogues (liraglutide).Lu 2025
—
Native GLP-1 efficacy
Minimal — rapid degradation prevents sustained appetite suppression
—
Gastric emptying
Delayed in animal models, contributing to satiety
—
Body weight impact
Not observed with native GLP-1 — requires analogue formulations
—
Weight gain reduction
—
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
Body fat reduction
—
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
Lipolytic activity
—
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
Insulin sensitivity
—
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
IGF-1 impact
—
No elevation — fragment does not activate GH/IGF-1 axis
Beta-3 AR dependency
—
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
Human evidence
—
None published — pre-clinical only
04Side Effects & Safety
Parameter
GLP-1 (7-37)
HGH Fragment 176-191
Native GLP-1
Well-tolerated in research settings; no prolonged exposure data
—
Hypoglycemia risk
Low — insulin secretion is glucose-dependent
—
Analogue side effects
Nausea, vomiting, diarrhea (GLP-1R agonists)
Not applicable to native GLP-1 due to non-therapeutic use.
—
GLP-1 resistance
High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016
—
Human safety data
—
Not available — no published human trials
Metabolic profile
—
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
Absolute Contraindications
GLP-1 (7-37)
—HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Relative Contraindications
GLP-1 (7-37)
—HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
05Administration Protocol
Parameter
GLP-1 (7-37)
HGH Fragment 176-191
1. Research use only
Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
2. Storage
Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
3. Clinical alternatives
For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).
Animal protocols: 14–19 days. Human duration not established — no published trials.
4. Storage
—
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
5. Detection
—
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015